Protalix BioTherapeutics (PLX) EBIT (2010 - 2026)

Protalix BioTherapeutics has reported EBIT for 17 years, with the latest figure at $4.7 million in Q2 2026.

• On a quarterly basis, EBIT rose 298.63% year-over-year to $4.7 million in Q2 2026; TTM through Jun 2026 was $23.3 million, a 183.1% increase from a year earlier, with the FY2025 full-year figure at -$5.5 million, down 240.41% from the prior year.
• EBIT was $4.7 million for Q2 2026 at Protalix BioTherapeutics, down from $21.1 million in the prior quarter.
• The five-year high for EBIT was $21.1 million in Q1 2026, with the low at -$5.6 million in Q4 2023.
• Average EBIT over 5 years is $1.2 million, with a median of -$2.2 million recorded in 2023.
• The sharpest annual moves came in 2025 and 2026: EBIT slumped 164.61% in 2025, then surged 610.16% in 2026.
• Over 5 years, EBIT stood at -$2.5 million in 2022, then slumped by 125.05% to -$5.6 million in 2023, then surged by 228.39% to $7.2 million in 2024, then plunged by 164.61% to -$4.7 million in 2025, then jumped by 200.3% to $4.7 million in 2026.
• The last three EBIT figures came in at $4.7 million (Q2 2026), $21.1 million (Q1 2026), and -$4.7 million (Q4 2025), per Business Quant data.